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Abstract
OBJECTIVE: To investigate the effect of Guben-
fangxiao decoction (GBFXD) on respiratory-syncy-
tial-virus (RSV) -induced asthma and the expression
of asthma susceptibility gene, orosomucoid 1-like
protein 3 (ORMDL3) in mice.
METHODS: Seventy-two female BALB/c mice were
randomly assigned to normal, model, GBFXD high
dose, GBFXD moderate dose, GBFXD low dose and
montelukast groups. An asthma model was in-
duced via intraperitoneal injection and aerosol in-
halation of ovalbumin (OVA) and repeated intrana-
sal instillation of RSV in all mice, except those in the
normal group. All treatments were administered at
the first onset of asthma (within 8 weeks of model
establishment) and the mice were euthanized after
28 days of treatment. The levels of transforming
growth factor-β (TGF-β) and interleukin-6 (IL-6) in
bronchoalveolar lavage fluid (BALF) of the mice
were measured and the expression of asthma sus-
ceptibility gene ORMDL3 in lung tissue was deter-
mined using real-time polymerase chain reaction
(RT-PCR) and western blotting.
RESULTS: Expression of ORMDL3 and levels of
TGF-β and IL-6 were significantly higher in the mod-
el group (P < 0.05, P < 0.01) compared with the nor-
mal mice. Levels of ORMDL3, TGF-β and IL-6 were
significantly lower in all three GBFXD treated
groups (P < 0.05) compared with the model group.
However, the levels in the GBFXD treatment groups
did not differ significantly from the montelukast
group.
CONCLUSION: GBFXD had a therapeutic effect in
this experimental model. The functional mecha-
nism of GBFXD may involve multiple factors, includ-
ing alleviation of airway inflammation, down-regu-
lation of asthma susceptibility gene ORMDL3 and
inhibition of airway remodeling.
© 2016 JTCM.
Key words: Asthma; ORMDL3 protein, mouse; Air-
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INTRODUCTION
Bronchial asthma is chronic inflammation of the air-
way, with both genetic and environmental factors im-
plicated in its pathogenesis.1,2 Recurrent asthma attacks
involve infiltration of inflammatory cells and abnormal
changes to the structure of the airway. The mechanism
underlying airway remodeling has yet to be deter-
mined. Recently, the first asthma-specific, ge-
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nome-wide association study (GWAS) identified oroso-
mucoid 1-like protein 3 (ORMDL3) as a candidate
asthma risk gene,3 in multiple ethnic groups.4-6 Howev-
er, the function of ORMDL3 remains unknown and
further studies are needed to elucidate the mechanisms
of ORMDL3 and its association with asthma. Guben-
fangxiao decoction (GBFXD) is prepared using a for-
mula containing eleven Chinese herbs. The formula
was designed by Professor Jiang Yuren for the manage-
ment of asthma and has been used in Jiangsu Province
Hospital of Traditional Chinese Medicine (TCM) for
more than 30 years. Our previous studies showed that
GBFXD could protect against airway inflammation
and inhibit airway hyperresponsiveness.7
The aim of the present study was to investigate the ef-
fect of GBFXD on respiratory-syncytial-virus
(RSV) -induced asthma and the expression of the asth-
ma susceptibility gene ORMDL3, in mice.
METHODS
Drug and reagents
GBFXD was prepared from a TCM formula consisting
of Huangqi (Radix Astragali Mongolici), Dangshen (Ra-
dix Codonopsis), Baizhu (Rhizoma Atractylodis Macro-
cephalae), Fuling (Poria), calcining Muli (Concha Os-
treae), Chantui (Periostracum Cryptotympanae), Chenpi
(Pericarpium Citri Reticulatae), Fangfeng (Radix Saposh-
nikoviae), Xinyi (Flos Magnoliae Biondii Immaturus),
Wuweizi (Fructus Schisandrae Chinensis) and stir-frying
with liquid adjuvant Gancao (Radix Glycyrrhizae). The
ratio of mass in grams used in the formula was 5∶3.3∶
3.3∶3.3∶5∶2∶2∶1∶2∶2∶1 and the granules were sup-
plied by Jiangsu Province Hospital of Traditional Chi-
nese Medicine. The decoction was produced using the
granules and double distilled water at a concentration
of 2.25 g/mL. Montelukast sodium tablets (20070058,
Hangzhou MSD pharmaceutical Co., Ltd., Hangzhou,
China) were used to prepare a solution of approximate-
ly 0.16 mg/mL, in sterile distilled and stored stored at
4 ℃ Ovalbumin (OVA) was supplied by Sigma (St.
Louis, MO, USA). Respiratory syncytial virus (RSV)
was obtained from the Institute of Pediatrics of Nan-
jing University of Chinese Medicine (Nanjing, China).
Enzyme-linked immunosorbent assay (ELISA) kits for
IL-13 and lL-6 were supplied by eBioscience (San Di-
ego, CA, USA). Real-time PCR master mix Plus
(SYBR Green) and RNA extraction kits were supplied
by Takara Biotechnology (Shanghai, China). Monoclo-
nal antibodies against ORMDL3 were supplied by Ab-
cam (Massachusetts, MA, USA) and against β-actin by
Santa Cruz (California, CA, USA). Secondary antibod-
ies were also supplied by Abcam. Primers for IL-13,
ORMDL3 and β-actin were designed and synthesized
by Takara Biotechnology.
Animals and asthma model establishment
Seventy-two healthy, female, 6-week-old BALB/c mice
［certificate of quality No. SCXK (Hu) 2012-0002］,
weighing [(18 ± 2) g] were supplied by the Laboratory
Animal Center of Shanghai Slack Co., Ltd., (Shanghai,
China). Mice received food and water ad libitum for 1
week before experiments [temperature at (24 ± 1) ℃
and humidity at 50% ± 5%]. Mice were maintained in
the Laboratory Animal Center in the Nanjing Universi-
ty of Traditional Chinese Medicine. All animal studies
were performed according to the Guide for the Care
and Use of Laboratory Animals of the National Insti-
tutes of Health. The protocol was approved by the Com-
mittee on the Ethics of Animal Experiments of the
Nanjing University of Traditional Chinese Medicine.
Mice were randomly divided into six groups: normal,
model, GBFXD high dose, GBFXD moderate dose,
GBFXD low dose and montelukast. Asthma was in-
duced in all mice, except those in the normal group. A
sensitization and challenge protocol was employed, as
described previously,8,9 with small modifications. Mice
were immunized via intraperitoneal injection of 100 μg
OVA, conjugated to 1 mg aluminum potassium sul-
fate, in a total volume of 0.2 mL on the 1st and 8th
day. Mice inhaled aeroallergens as 2.5% OVA, every
day from the 15th to the 28th day, for 30 min. Asthma
was induced using intranasal instillation of 50 μL RSV
on the 29th, 42nd, and 55th day. From the 29th to the
55th day, mice were challenged with inhalation of
2.5% OVA solution for 30 min, once every 3 days.10
GBFXD treatment
The standard dose of GBFXD was based on individual
animal body weight. The formula used was Db = Da ×
Rab, which was derived from the formula used to deter-
mine the standard dose for humans.11 The formula
used for humans was based on a ratio of 24 g crude
medicine to 1 kg of murine body weight. GBFXD
high-dose (GBFXD- H) was 36 g/kg, the moderate
dose (GBFXD-M) was 24 g/kg and the low dose (GB-
FXD-L) was 12 g/kg. GBFXD and montelukast ace-
tate (2.6 mg/kg) treatments were intragastrically admin-
istered, once a day from the 2nd day of model estab-
lishment. The normal and model groups were given an
equal volume of distilled water, intragastrically at the
same time points. All mice were euthanized after 28
days of treatment.
RSV
RSV supernatants were prepared according to the
method described previously.12 The 50% tissue culture
infective dose (TCID50) of RSV was measured as 1.0×
106.5TCID50/mL.
Bronchoalveolar lavage fluid collection
Mice were sacrificed 24 h after the final treatment.
BALF was acquired as described previously.7 Three ali-
quots of 0.5 mL PBS were injected and withdrawn
through a tracheal cannula. Following centrifugation,
the supernatant was stored at － 70 ℃ , for measure-
ment of IL-6 and TGF-β concentrations, using ELISA.
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Lung histology and morphometry
The left lungs of mice were fixed in 4% buffered para-
formaldehyde for at least 24 h. Transverse sections of
5 μm were harvested. Each section was stained with he-
matoxylin and eosin for histological assessment using
light microscopy. Additional sections were stained with
Masson's trichrome to detect collagen deposition and
periodic acid Schiff (PAS) stain to show mucin within
goblet cells. For sections stained with Masson's tri-
chrome, the region of interest was a 20 μm band, im-
mediately beneath the epithelium, as this is considered
to include the ECM and contractile elements associat-
ed with the airways.13 The positive peribronchiole areas
stained with Masson's trichrome were quantified using
light microscopy connected to an Image-Pro Plus im-
age analysis system (Media Cybernetics, Chicago, IL,
USA). The numbers of PAS-positive epithelial cells
(goblet cells) in individual bronchioles were counted as
previously described.14 At least six bronchioles were
counted on each slide and all the histological analyses
were performed blind to treatment.
RT-PCR determination of ORMDL3 expression in
lungs
The lungs of mice were collected after the final treat-
ment. Total RNA from lung tissue was extracted using
TRIzol reagent, according to the manufacturer's in-
structions. The concentration of RNA was measured
using spectrophotometry. Total RNA was reverse tran-
scribed to cDNA, using reverse transcriptase reagents
from Takara, according to the manufacturer's protocol.
Real-time polymerase chain reaction (RT-PCR) was
carried out using SYBR GreenⅡ fluorescent dye meth-
od, on Applied Biosystems 7500 PCR apparatus (Cali-
fornia, CA, USA). The sequences of primers used are
shown in Table 1.
Western blotting
Protein was extracted from lungs using protein lysate
from Beyotime Biotechnology (Haimen, China). It
contained 50 mmol/L Tris-Cl (pH 7.4), 150 mmol/L
NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS, 100 μg/mL phenylmethylsulfonyl (PMSF)
and 1 μg/mL aprotinin. The protein concentration was
measured using a BCA protein assay kit from Pierce
(Rockford, IL, USA). Sample aliquots, containing 30 μg
protein, were fractionated on 12% SDS-polyacryl-
amide gels (SDS-PAGE) and transferred to polyvinyli-
dene fluoride (PVDF) membranes, from Millipore
(Massachusetts, MA, USA). The membranes were
blocked with 5% non-fat milk in 1×Tris-buffered sa-
line, with 0.1% Tween-20 (TBST) for 2 h at room
temperature and incubated overnight with anti-ORM-
DL3 (1∶500 final dilution) antibody. After incubation,
the blots were washed with 1 × TBST (20 mmol/L
Tris-HCl, pH 7.4, 150 mmol/L NaCl, and 0.1%
Tween-20) 3 times for 10 min. Membranes were then
incubated with secondary antibody (1∶5000 final dilu-
tion) at room temperature for 2 h and washed 3 times,
for 5 min, with 1 × TBST. The blots were visualized us-
ing a chemiluminescence system from Pierce, accord-
ing to the manufacturer's instructions. The results were
normalized using β-actin densitometry on an Im-
age-Pro Plus image analysis system.
Statistical analysis
All data were analyzed by using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA). Results are expressed as mean ±
standard deviation ( xˉ ± s). Differences between
groups were evaluated with one-way analysis of vari-
ance. P < 0.05 was considered significant.
RESULTS
Histopathological examination
Compared with the normal group, there was little eo-
sinophil infiltration and thicker airway and alveolar
walls in the model group. The levels of eosinophil infil-
tration in the GBFXD treatment groups were lower
than in the model group (P < 0.01). However, there
were no significant differences among the groups treat-
ed with GBFXD and montelukast (P < 0.05, Figure 1).
Compared with the normal group, collagen deposition
throughout the lung interstitium, around the wall of
airway, was significantly different (P < 0.01) in the
model group. There was a significant reduction in colla-
gen deposition in the GBFXD and montelukast treat-
ment groups (P < 0.05, Table 2 and Figure 2). The
number of goblet cells that stained positively for mucin
was significantly increased in the model group com-
pared with the normal group. The GBFXD treatment
groups showed a sharp decrease in the presence of mu-
cin compared with the model group (P < 0.05, Table 3
and Figure 3).
Levels of IL-6 and TGF-β in BALF supernatant
The IL-6 and TGF-β levels were very low in the nor-
Gene
GAPDH
ORMDL3
Primer
Forward: 5'-cgtgttcctacccccaatgt-3'
Reverse: 5'-tgtcatacttggcaggtttct-3'
Forward: 5'-cactgggagcagatggactac-3'
Reverse: 5'-tggacttggtcatacttggtgt-3'
Product annealing
104 bp 58℃
106 bp 58℃
Table 1 The sequences of forward and reverse primers of ORMDL3
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mal group and significantly elevated in the model
group. IL-6 and TGF-β levels in the DBFXD groups
were significantly lower than those in the model group
(P < 0.05). There were no significant differences be-
tween the levels among the GBFXD and montelukast
groups. The results of the enzyme-linked immunosor-
bent assay indicated that GBFXD ameliorated airway
inflammation in mice (Table 3).
Changes in ORMDL3 mRNA expression in lung
tissue
The relative quantity of ORMDL3 mRNA expression
in lung tissue of the model group (2.30 ± 0.19 fold
change) was significantly higher than that of the nor-
mal group (P < 0.05, P < 0.01). Compared with the
model group, ORMDL3 mRNA expression in all treat-
ment groups was downregulated (P < 0.05, P < 0.01).
There were no significant differences in expression
among the GBFXD and montelukast groups (P >
0.05, Table 3 and Figure 4).
DISCUSSION
In this study, GBFXD reduced the levels of Th2-type
cytokines, IL-6 and TGF-β, in an RSV enhanced asth-
ma model. Investigations have shown that IL-6 can
promote allergen-induced epithelial cell damage, gob-
let cell hyperplasia with mucus hyperproduction and
the production of TGF-β.21 TGF-β has also been re-
ported to play a detrimental role in promoting airway
remodeling during chronic inflammation associated
with asthma. Therefore, GBFXD showed a positive ef-
fect by inhibiting Th2-type cytokines and airway re-
modeling.
Subepithelial fibrosis represents an important feature
of asthmatic bronchi. In our study, even at 4 weeks af-
ter the final allergen exposure the model group mice de-
veloped universal collagen deposition, which may con-
tribute to a prolonged airway inflammatory response.
GBFXD could significantly reduce collagen deposi-
tion. We also examined goblet cells, which are the
main source of mucin glycoproteins. Interestingly, GB-
FXD not only inhibited mucin production and colla-
gen deposition but also reduced IL-6 and TGF-β lev-
els. This suggests that the GBFXD effects on mucin
production and collagen deposition may be associated
with the suppression of Th2 cytokines.
ORMDL3 has been identified as a candidate risk gene
for asthma. Consistent with this finding, ORMDL3
was significantly increased in the blood of recurrent
wheeze patients.22ORMDL3 proteins are negative regu-
lators of sphingolipid synthesis, which may contribute
to the development of childhood asthma.23 ORMDL3
was recently shown to be involved in Ca2 + signaling
and the unfolded protein response (UPR), which can
lead to inflammatory responses in asthma.24 In our
study, GBFXD had a significant effect on ORMDL3
expression, at both mRNA and protein levels. ORM-
DL3 is an inducible lung epithelial gene that regulates
oligoadenylate synthetase (OAS) genes,25 which sug-
gests it may play an antiviral role in RSV.26
In conclusion, this study provides evidence that by re-
ducing airway inflammation, decreasing airway colla-
gen deposition, inhibiting airway mucus production
and downregulating ORMDL3 expression, GBFXD
treatment can prevent the development of chronic
asthma. However, the mechanism of action of GB-
FXD on ORMDL3 expression and its function in
the pathogenesis of asthma remains unclear. It is pos-
sible that ORMDL3 selectively regulates activation of
the endoplasmic reticulum localized transcription fac-
tor, ATF6α, which is linked to the sarcoendoplasmic
A B C
D E F
Figure 1 Histopathological analysis of a lung section (HE staining, × 100 )
A: airway inflammation of normal group; B: airway inflammation of model group; C: airway inflammation of montelukast group;
D: airway inflammation of GBFXD-H group; E: airway inflammation of GBFXD-M group; F: airway inflammation of GBFXD-L group.
The normal group was treated with distilled water only; the model group was exposed to OVA and treated with distilled water;
the montelukast group was exposed to OVA and treated with montelukast acetate (2.6 mg/kg); the GBFXD-H group was exposed
to OVA and treated with GBFXD (36 g/kg); the GBFXD-M group was exposed to OVA and treated with GBFXD (24 g/kg); the GB-
FXD-L group was exposed to OVA and treated with GBFXD (12 g/kg). OVA: ovalbumin; GBFXD: Gubenfangxiao decoction; GB-
FXD-H: Gubenfangxiao high-dose decoction; GBFXD-M: Gubenfangxiao moderate dose decoction; GBFXD-L: Gubenfangxiao low
dose decoction. HE: hematoxylin-eosin. Normally, few eosinophils could be seen in the lung, while OVA sensitization and chal-
lenge led to significantly augmented recruitment of eosinophils to the airway (B vs A, P < 0.01). Both montelukast and GBFXD
treatment effectively diminished tissue infiltration of eosinophils (C, D, E, F vs B, P < 0.05).
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reticulum, Ca2 + ATPase (SERCA2b), and implicated
in airway remodeling in asthma.27 Further investiga-
tion of GBFXD is required to elucidate its mecha-
nism of action.
Group
Normal
Model
Montelukast
GBFXD-H
GBFXD-M
GBFXD-L
n
12
12
12
12
12
12
Collagen staining area
(μm2/μm %)
8.11±1.20
43.35±5.52a
26.02±2.13b
19.05±1.66b
14.05±1.36b
17.05±1.34b
PAS positive epithelial cells
(%)
6.78±0.34
25.99±1.18a
13.46±1.17b
12.54±1.88b
13.24±0.33b
14.68±0.58
ORMDL3/actin
0.15±0.07
2.27±0.05a
0.10±0.03b
0.07±0.03b
0.12±0.04b
0.48±0.10b
Notes: the normal group was treated with distilled water only; the model group was exposed to OVA and treated with distilled water; the
montelukast group was exposed to OVA and treated with montelukast acetate (2.6 mg/kg); the GBFXD-H group was exposed to OVA
and treated with GBFXD (36 g/kg); the GBFXD-M group was exposed to OVA and treated with GBFXD (24 g/kg); the GBFXD-L
group was exposed to OVA and treated with GBFXD (12 g/kg). OVA: ovalbumin; GBFXD-H: Gubenfangxiao decoction high dose; GB-
FXD-M: Gubenfangxiao decoction moderate dose; GBFXD-L: Gubenfangxiao decoction low dose; PAS: periodic acid Schiff; ORMDL3:
orosomucoid 1-like protein 3. Compared with the normal group, aP < 0.01; compared with the model group, bP < 0.01.
Table 2 Changes in collagen deposition for each group ( xˉ ± s)
Group
Normal
Model
Montelukast
GBFXD-H
GBFXD-M
GBFXD-L
n
12
12
12
12
12
12
Dose (g/kg)
-
-
0.0026
36
24
12
IL-6 (pg/mL)
74.070±7.842
281.101±18.522a
150.478±4.272b
64.478±9.217b
42.745±12.276b
51.762±12.841b
TGF-β (ng/mL)
3.145±0.021
3.402±0.081a
3.068±0.03b
3.235±0.026b
3.221±0.058b
3.147±0.060b
Notes: the normal group was treated with distilled water only; the model group was exposed to OVA and treated with distilled water; the
montelukast group was exposed to OVA and treated with montelukast acetate (2.6 mg/kg); the GBFXD-H group was exposed to OVA
and treated with GBFXD (36 g/kg); the GBFXD-M group was exposed to OVA and treated with GBFXD (24 g/kg); the GBFXD-L
group was exposed to OVA and treated with GBFXD (12 g/kg). OVA: ovalbumin; GBFXD-H: Gubenfangxiao decoction high dose; GB-
FXD-M: Gubenfangxiao decoction moderate dose; GBFXD-L: Gubenfangxiao decoction low dose; BALF: bronchoalveolar lavage fluid;
TGF-β: transforming growth factor-β; IL-6: interleukin-6. Compared with the normal group, aP < 0.01; compared with the model group,
bP < 0.01.
Table 3 The levels of IL-6 and TGF-β in BALF supernatant for each group ( xˉ ± s)
Figure 2 Staining as assessed using morphometry for collagen deposition (Masson's staining, ×100)
A: collagen deposition of normal group; B: collagen deposition of model group; C: collagen deposition of montelukast group; D:
collagen deposition of GBFXD-H group; E: collagen deposition of GBFXD-M group; F: collagen deposition of GBFXD-L group. The
normal group was treated with distilled water only; the model group was exposed to OVA and treated with distilled water; the
montelukast group was exposed to OVA and treated with montelukast acetate (2.6 mg/kg); the GBFXD-H group was exposed to
OVA and treated with GBFXD (36 g/kg); the GBFXD-M group was exposed to OVA and treated with GBFXD (24 g/kg); the GBFXD-L
group was exposed to OVA and treated with GBFXD (12 g/kg). OVA: ovalbumin; GBFXD: Gubenfangxiao decoction; GBFXD-H:
Gubenfangxiao high-dose decoction; GBFXD-M: Gubenfangxiao moderate dose decoction; GBFXD-L: Gubenfangxiao low dose
decoction. Mucus overproduction was evident in the model group (H vs G, P < 0.01). Mucus production was clearly reduced in the
lungs of GBFXD and montelukast treatment groups (C, D, E, F vs B, P < 0.05).
A B C
D E F
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